Matinas BioPharma to Present at the Needham Healthcare Conference
April 08, 2021 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present...
Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
March 29, 2021 06:30 ET
|
Matinas BioPharma Holdings, Inc.
– Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics – – Enrollment continues in second patient cohort of EnACT study...
Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021
March 15, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
Matinas BioPharma to Present at the Barclays Global Healthcare Conference
March 01, 2021 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present...
Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®
February 01, 2021 06:00 ET
|
Matinas BioPharma Holdings, Inc.
– LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa® – – LYPDISO™ demonstrated a 39% relative difference in response...
Matinas BioPharma to Present at the ICR Conference 2021
January 06, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a...
Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001
January 04, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
December 07, 2020 06:35 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders
December 07, 2020 06:30 ET
|
Matinas BioPharma Holdings, Inc.
- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 - - Company’s Proposal...
Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer
December 01, 2020 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...